Homepage
Medication Guide
Indications for Cobenfy (KarXT)
Cobenfy (KarXT) is an innovative oral capsule medication approved by the U.S. Food and Drug Administration (FDA) in 2024, specifically indicated for the treatment of schizophrenia in adults. This medi...
507
Tuesday, November 11th, 2025, 10:34
How to Purchase Cobenfy (KarXT)
Cobenfy (KarXT) is a new antipsychotic drug approved in 2024. Its dual mechanism of action provides a new option for patients with schizophrenia. As a strictly controlled prescription drug, standardiz...
505
Tuesday, November 11th, 2025, 10:31
What Are the Side Effects of Perfluorohexyl Octane Eye Drops (Miebo)?
Perfluorohexyl Octane Eye Drops (Miebo) is a new dry eye treatment drug approved in the United States in 2023, with its active ingredient being 100% perfluorohexyl octane.What Are the Side Effects of ...
505
Tuesday, November 11th, 2025, 10:27
Precautions for Using Perfluorohexyl Octane Eye Drops (Miebo)
Perfluorohexyl Octane Eye Drops (Miebo) is a new type of semifluorinated alkane eye drops. Approved in the United States in 2023, it is specifically used to treat the signs and symptoms of dry eye dis...
505
Tuesday, November 11th, 2025, 10:24
How to Use Perfluorohexyl Octane Eye Drops (Miebo)
Perfluorohexyl Octane Eye Drops (Miebo) is a semifluorinated alkane ophthalmic solution. It was first approved in the United States in 2023 and is specifically used to treat the signs and symptoms of ...
503
Tuesday, November 11th, 2025, 10:21
Indications of Perfluorohexyl Octane Eye Drops (Miebo)
Perfluorohexyl Octane Eye Drops (Miebo) is a new ophthalmic therapeutic drug approved by the U.S. Food and Drug Administration (FDA) in 2023, providing an innovative treatment option for patients with...
503
Tuesday, November 11th, 2025, 10:01
How to Purchase Perfluorohexyl Octane Eye Drops (Miebo)
Perfluorohexyl Octane Eye Drops (Miebo) is a new dry eye treatment drug approved in 2023. Its unique evaporation-inhibiting effect provides a new option for patients with dry eye syndrome.How to Purch...
505
Tuesday, November 11th, 2025, 09:56
Precautions for Wayrilz (Rezabrutinib) Administration
Wayrilz (Rezabrutinib) is a Bruton's Tyrosine Kinase inhibitor, first approved in the United States in 2025. It is primarily indicated for the treatment of persistent or chronic immune thrombocyto...
508
Monday, November 10th, 2025, 13:07
What Are the Side Effects of Wayrilz (Rezabrutinib)?
Wayrilz (Rezabrutinib) is an oral Bruton's Tyrosine Kinase inhibitor. Approved by the U.S. FDA in 2025, it is indicated for the treatment of persistent or chronic immune thrombocytopenia in adults...
505
Monday, November 10th, 2025, 11:44
How to Purchase Wayrilz (Rezabrutinib)
Wayrilz (Rezabrutinib) is a novel Bruton's Tyrosine Kinase (BTK) inhibitor. Approved in the United States in 2025, it is indicated for the treatment of persistent or chronic immune thrombocytopeni...
502
Monday, November 10th, 2025, 11:41
55 / 200
1996 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved